Hidradenitis Suppurativa: Epidemiology and Comorbidities

The presentation discusses Hidradenitis Suppurativa (HS), focusing on its epidemiology and significant comorbidities. It notes that HS affects approximately 1% of the population, with higher prevalence in black individuals and varying detection rates due to self-reporting biases. The speaker emphasizes the importance of recognizing an expanding list of comorbidities, which are essential for effective patient management and treatment decisions. The presentation highlights various comorbidities, such as inflammatory arthritis, inflammatory bowel disease, and hormonal conditions like PCOS, noting how they impact treatment strategies. A particular point was made about the relationship between HS and chronic conditions, such as inflammatory arthritis being three times more prevalent in HS patients compared to controls. Additionally, the presentation underscores the need for multidisciplinary management, especially when patients present with complications like perianal fistulas or when inflammatory bowel disease is suspected. The speaker encourages dermatologists to be aware of accompanying conditions to optimize treatment and discusses the demographics of HS patients, including underrepresented groups such as South Asians and those of Arabic descent. The session concludes by stating that while the true prevalence of HS remains undefined, recognizing its comorbidities is crucial for appropriate patient care.